Topical JAK Inhibitor Shows Improvement for PN

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a phase 3 trial shows.
Medscape Medical News

source https://www.medscape.com/viewarticle/topical-ruxolitinib-improves-itch-blistering-prurigo-2025a10006b2?src=rss

Comments

Popular posts from this blog

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

New AAFP practice guideline sets blood pressure targets for adults with hypertension